To further confirm that CDK9i restrains the glycolytic metabolism of B-ALL cells in vitro, we used AZD4573, a highly selective CDK9 inhibitor, to evaluate the effects of CDK9i on the cell apoptosis of B-ALL cells. This evidence concerns the gene CDK9 and acute lymphoblastic leukemia.